Abstract:What's new? Different carcinogenic pathways have specific mutational signatures, which can provide details about gene defects related to cancer development and prognosis. Little is known, however, about associations between mutational signature activity and cancer outcome. Here, using data from The Cancer Genome Atlas (TCGA) database, the authors identify several mutational signatures that provide prognostic information for most cancer types. In particular, distinct cancer type‐specific differences in gene expression were observed between low‐ and high‐activity mutational signatures. The findings offer insight into a possible prognostic role for mutational signatures and could help further understanding of the etiology of mutational patterns in cancer. Different endogenous and exogenous mutational processes cause specific patterns of somatic mutations and mutational signatures. Although their biological research has been intensive, there are only rare studies assessing the possible prognostic role of mutational signatures. We used data from The Cancer Genome Atlas to study the associations between the activity of the mutational signatures and four survival endpoints in 18 types of malignancies. We further explored the prognostic differences according to, for example, the HPV status in head and neck squamous cell carcinomas and smoking status in lung cancers. The predictive power of the signatures over time was evaluated with a dynamic area under the curve model, and the links between mutational signature activities and differences in gene expression patterns were analyzed. In 12 of 18 studied cancer types, we identified at least one mutational signature whose activity predicted survival outcomes after adjusting for the established prognostic factors. For example, overall survival was associated with the activity of mutational signatures in nine cancer types and disease‐specific survival in seven cancer types. The clock‐like signatures SBS5 and SBS40 were most commonly associated with survival endpoints. The genes of the myosin binding protein and melanoma antigen families were among the most substantially dysregulated genes between the signatures of low and high activity. The differences in gene expression also revealed various enriched pathways. Based on these data, specific mutational signatures associate with the gene expression and have the potential to serve as strong prognostic factors in several cancer types.

Somatic Gene Mutation Signatures Predict Cancer Type and Prognosis in Multiple Cancers with Pan-Cancer 1000 Gene Panel.

A Multi-Gene Model Effectively Predicts the Overall Prognosis of Stomach Adenocarcinomas with Large Genetic Heterogeneity Using Somatic Mutation Features.

Tumor Mutation Burden Analysis in a 5,660 Cancer Patient Cohort Reveals Cancer Type-Specific Mechanisms for High Mutation Burden.

Identification of Tumor Mutation Burden, Microsatellite Instability, and Somatic Copy Number Alteration Derived Nine Gene Signatures to Predict Clinical Outcomes in STAD.

A Somatic Mutation-Derived Lncrna Signature Of Genomic Instability Predicts Prognosis For Patients With Liver Cancer

Prognostic Gene Expression Signature Revealed the Involvement of Mutational Pathways in Cancer Genome

Common Human Cancer Genes Discovered by Integrated Gene-Expression Analysis

Mutational signatures and their association with cancer survival and gene expression in multiple cancer types

Multi gene mutation signatures in colorectal cancer patients: predict for the diagnosis, pathological classification, staging and prognosis

Comprehensive identification of survival-associated genes for cancers

Mutational landscape and significance across 12 major cancer types

Prognostic genome and transcriptome signatures in colorectal cancers

The signature of pharmaceutical sensitivity based on ctDNA mutation in eleven cancers.

Toward the precision breast cancer survival prediction utilizing combined whole genome-wide expression and somatic mutation analysis

Improvement in prediction of prostate cancer prognosis with somatic mutational signatures

Pan-cancer Transcriptome Analysis Reveals a Gene Expression Signature for the Identification of Tumor Tissue Origin.

A Gene Signature Associated with Prognosis and Immune Processes in Head and Neck Squamous Cell Carcinoma

Genetic Determinants of Somatic Selection of Mutational Processes in 3,566 Human Cancers

Distinguishable Prognostic Signatures and Tumor Immunogenicity Between Pancreatic Head Cancer and Pancreatic Body/Tail Cancer

Survival prediction model for non-small cell lung cancer based on somatic mutations.

Survival prediction for patients with lung adenocarcinoma: A prognostic risk model based on gene mutations